At‑Home Lasix ONYU Drives Fintech Demand; Block (SQ) Positioned for Specialty Payments

Fintech-readiness for at-home specialty drug delivery

Fintech platforms such as Block are positioned to play a central role as SQ Innovation brings Lasix ONYU to national specialty distribution, creating immediate operational and payment needs across outpatient and home‑based care. The product’s model — a prefilled, high‑concentration furosemide cartridge designed for selected patient self‑administration — requires coordination among hospitals, home infusion providers, community pharmacies and specialty distributors. That network opens demand for integrated payment, billing and reconciliation services that Block already provides to small businesses and healthcare merchants.

Reimbursement complexity around Medicaid rebates and 340B participation further drives demand for software and payments orchestration. SQ Innovation’s execution of a Medicaid National Drug Rebate Agreement and distribution through Cardinal Health and Cencora means providers must track payer mixes, manage 340B eligibility and reconcile manufacturer and government rebates. Fintech firms can streamline claims adjudication, patient cost-sharing collection, subscription or recurring‑dose billing and split‑payments between providers and payers, reducing administrative friction that can delay home treatment adoption.

Practical product integrations offer a route for Block to expand its healthcare footprint without entering clinical delivery. Features such as secure patient billing portals, automated recurring payments, inventory‑aware point‑of‑sale for pharmacies, scheduling and delivery payments for home‑infusion logistics, and compliance‑focused reporting align with the needs created by Lasix ONYU’s home‑use model. Partnerships with clinical networks for training and care‑pathway documentation — combined with Block’s merchant tools — could accelerate outpatient alternatives to emergency and inpatient care while addressing data security and regulatory requirements.

Lasix ONYU regulatory and distribution specifics

SQ Innovation announces that Lasix ONYU, approved by the U.S. FDA on Oct. 7, 2025 for edema due to fluid overload in adults with chronic heart failure, is now orderable through Cardinal Health’s Specialty Pharmaceutical Distribution and Cencora’s Specialty Distribution. The product uses a 30 mg/mL furosemide formulation in a pre‑filled glass cartridge intended to enable prescribed at‑home administration when clinicians determine it appropriate.

Access, training and clinical rollout

The company reports a Medicaid NDRA and 340B access for eligible hospitals, facilities and pharmacies, and posts ordering information at lasix-onyu.com/order. SQ Innovation says it will collaborate with the clinical community to develop evidence‑based care pathways and training materials to support safe self‑administration or caregiver‑assisted dosing in outpatient settings.